Study of the Effect of GS-6615 in Subjects With LQT-3
NCT01849003
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Long QT Syndrome
Interventions
DRUG:
GS-6615
Sponsor
Gilead Sciences